Microbiology and Immunology

You are here

Publications

Found 25 results

Filters: Author is Ketas, Thomas J [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Ingallinella P, Bianchi E, Ladwa NA, Wang Y-J, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD et al.. 2009. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.. Proc Natl Acad Sci U S A. 106(14):5801-6.

Ketas TJ, Chaturbhuj D, Portillo VMCruz, Francomano E, Golden E, Chandrasekhar S, Debnath G, Díaz-Tapia R, Yasmeen A, Kramer KD et al.. 2021. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.. Pathog Immun. 6(1):116-134.

C

Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens A-J, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E et al.. 2018. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.. Biotechnol Bioeng. 115(4):885-899.

Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al.. 2019. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)

Colin P, Ringe RP, Yasmeen A, Ozorowski G, Ketas TJ, Lee W-H, Ward AB, Moore JP, Klasse PJ. 2023. Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.. Retrovirology. 20(1):9.

Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al.. 2021. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.

E

Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJohan, Moore JP. 2007. Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.. Virology. 364(2):431-40.

Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJohan. 2012. Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.. Virology. 422(1):22-36.

Banerjee K, Andjelic S, Klasse PJohan, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP. 2009. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.. Virology. 389(1-2):108-21.

Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC et al.. 2018. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.. PLoS Pathog. 14(2):e1006913.

G

Caniels TG, Medina-Ramírez M, Zhang S, Kratochvil S, Xian Y, Koo J-H, Derking R, Samsel J, van Schooten J, Pecetta S et al.. 2024. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.. Sci Immunol. 9(98):eadk9550.

Schorcht A, Cottrell CA, Pugach P, Ringe RP, Han AX, Allen JD, van den Kerkhof TLGM, Seabright GE, Schermer EE, Ketas TJ et al.. 2022. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.. J Virol. 96(1):e0155221.

H

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al.. 2015. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science. 349(6244):aac4223.

I

Pugach P, Ray N, Klasse PJohan, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP. 2009. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.. Virology. 387(2):296-302.

L

Prabhu M, Yang YJ, Johnston CD, Murphy EA, Ketas TJ, Díaz-Tapia R, Jurkiewicz M, Racine-Brzostek S, Mohammed I, Sukhu AC et al.. 2023. Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.. Am J Obstet Gynecol MFM. 5(2):100796.

N

Pugach P, Ketas TJ, Michael E, Moore JP. 2008. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.. Virology. 377(2):401-7.

Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP. 2008. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.. Virology. 372(1):187-200.

P

Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al.. 2021. Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.

Veazey RS, Klasse PJohan, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ et al.. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.. Nature. 438(7064):99-102.

Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP. 2010. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.. J Infect Dis. 202(5):739-44.

R

Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJohan, Moore JP. 2011. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.. Virology. 413(1):47-59.

Anastassopoulou CG, Ketas TJ, Klasse PJohan, Moore JP. 2009. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.. Proc Natl Acad Sci U S A. 106(13):5318-23.

S

W Horne S, Johnson LM, Ketas TJ, Klasse PJohan, Lu M, Moore JP, Gellman SH. 2009. Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.. Proc Natl Acad Sci U S A. 106(35):14751-6.

R Malcolm K, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJohan et al.. 2012. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.. Antimicrob Agents Chemother. 56(5):2251-8.

T

Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PAD, Lee WT, McDonough KA, Qiu Y, Ketas TJ et al.. 2021. Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients.. Biosens Bioelectron. 178:113008.